GET DAILY SIGNALSOmeros Corporation (OMER): Is a Move to the $27.50 Analyst Target in Reach?
Key Takeaways
- The $27.50 central target represents the average of two current analyst price targets: $22 from Cantor Fitzgerald and $33 from H.C. Wainwright.
- The range between those targets is broad, from $22 to $33, highlighting differing views on how the commercial launch will unfold.
- From a recent price near $17.99, achieving $27.50 would mean an advance of roughly 53%.
- Support for the stock comes primarily from the U.S. launch of Yartemlea and the strategic partnership with Novo Nordisk that bolsters the balance sheet.
- Key risks include the European regulatory setback, limited analyst coverage, and uncertainty around execution in a new product launch.
- Additional details on this ticker are available through its Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Coverage and Price Targets
Coverage of OMER remains limited. Only two firms currently publish price targets. H.C. Wainwright’s Brandon Folkes maintains a Buy rating and a $33 target, which was reduced from $40 in October 2026 following the negative opinion from the European Medicines Agency’s CHMP. Cantor Fitzgerald’s Olivia Brayer Saunders rates the shares Overweight with a $22 target, an upgrade issued in September 2026. Needham continues to hold a neutral stance without an assigned target.
Averaging the two published targets produces the $27.50 figure, with the spread between $22 and $33 underscoring a clear difference in outlook. Bulls focus on commercial momentum and pipeline potential, while more cautious observers emphasize the European rejection and the inherent challenges of forecasting a biotech product launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Valuation and Required Move
Shares of Omeros Corporation have recently traded near $17.99, corresponding to a market capitalization of approximately $1.3 billion. Reaching the $27.50 level would require an increase of about 53%, a substantial move under any circumstances. The stock has shown considerable volatility, with a 52-week range stretching from roughly $6.24 to $21.24 following a recovery from much lower levels in prior years.
Any sustained advance would likely depend on continued U.S. prescription growth for Yartemlea, the upcoming third-quarter results scheduled for November 16, 2026, and further progress across the complement pipeline. Because the company is still in an early commercial phase, traditional earnings-based valuation models do not apply, leaving sentiment and clinical or commercial developments as the primary drivers.
Factors That Could Support Higher Prices
- Yartemlea launch progress. Recent analyst commentary has pointed to accelerating prescriptions and improving reimbursement patterns as important contributors to trading activity.
- Novo Nordisk collaboration. The agreement, which includes up to $240 million in upfront payments and as much as $2.1 billion in total potential value plus royalties, should help reduce near-term debt and extend cash reserves.
- Pipeline flexibility. Omeros retains rights to MASP-3 small molecules, the MASP-2 franchise, and earlier-stage programs in oncology and infectious diseases.
- Reimbursement infrastructure. Established ICD-10 and CPT codes, together with a pending NTAP decision, may facilitate broader hospital adoption.
Potential Obstacles to Reaching the Target
- European regulatory outcome. The CHMP’s negative opinion led the EMA to decline approval for narsoplimab in TA-TMA, triggering both a sharp share-price drop and the reduction in the H.C. Wainwright target.
- Launch execution challenges. Forecasting prescription trends for a new biotech product is difficult, and actual results could fall short of expectations.
- Limited coverage and wide dispersion. With only two published targets spanning $22 to $33, any single revision could materially shift the average.
- Capital and dilution considerations. Although the Novo Nordisk deal provides relief, a company with modest product revenue remains exposed to future financing needs.
Technical Context
From a chart perspective, the $21.24 area represents the 52-week high and a significant resistance level; a sustained break above it would be required to expand the recent trading range. Support has appeared in the $16–$17 zone during pullbacks. The longer-term structure has improved markedly from the distressed levels near $2 seen in 2022–2023, yet the wide range continues to reflect the volatility typical of small-cap biotech names.
Key Items to Watch
Analyst targets generally reflect a roughly 12-month horizon. Investors should focus on third-quarter earnings due November 16, 2026, updates on Yartemlea prescriptions and reimbursement, any further developments in the European regulatory process, milestones related to the Novo Nordisk transaction, and potential new analyst commentary given the thin coverage.
Final Assessment
The $27.50 central target for Omeros Corporation is simply the arithmetic mean of the two published analyst targets and implies an advance of approximately 53% from recent levels near $17.99. The bullish scenario centers on successful U.S. commercial execution, the Novo Nordisk partnership, and pipeline optionality, while the more cautious case highlights the European setback, launch uncertainties, and the broad dispersion of targets. With earnings imminent and coverage limited, the shares are likely to remain sensitive to news flow. Reaching the target will depend on catalysts that are inherently difficult to predict, and no price objective should be viewed as assured.
Using AI Daily Buy/Sell Signals in Research
In my own work, I often turn to Tickeron’s AI Daily Buy/Sell Signals for an additional quantitative perspective. The system applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals based on technical and market dynamics, offering a systematic complement to fundamental analysis when evaluating opportunities in fast-moving sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OMER in downward trend: price dove below 50-day moving average on October 30, 2026
OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 27 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 74 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OMER's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for OMER just turned positive on November 11, 2026. Looking at past instances where OMER's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.498). P/E Ratio (8.812) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry Biotechnology
Advertisement